The Benefit-Risk Balance — A Continuous Reassessment

The fundamental question that pharmacovigilance answers throughout the drug safety lifecycle is: does this medicine still do more good than harm, for the patients currently using it, under the current conditions of use? This question cannot be answered once. Conditions change — new patient populations, new concomitant medicines, new evidence of effectiveness, new safety signals. The benefit-risk balance is therefore not a verdict delivered at approval; it is a continuously updated assessment revisited with every significant new piece of safety or efficacy information.

Quantitative benefit-risk tools — including Multi-Criteria Decision Analysis (MCDA) frameworks developed under the EMA’s PROTECT project — provide structured methods for comparing benefits and risks using weighted criteria. These tools are increasingly used in PBRER benefit-risk sections and in ad hoc regulatory assessments triggered by significant new signals. AI-assisted MCDA is an emerging area, with several MAHs piloting models that can update benefit-risk estimates in near-real-time as new real-world evidence and spontaneous report data becomes available.

This lesson is, in a sense, the philosophical center of the entire lifecycle you’ve just walked through: every table, every timeline, every AI tool covered in this module exists in service of one continuously re-asked question. When you’re deep in MedDRA coding or narrative writing, it’s easy to lose sight of that — but every case you process is, ultimately, one data point in an ongoing argument about whether a specific medicine still deserves the trust patients are placing in it.